Product Description
Mechanisms of Action: Immunosuppressive
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Percutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Colombia
Approved Indications: None
Known Adverse Events: None
Company: Medtronic
Company Location: DUBLIN L2 2
Company CEO: Geoffrey S. Martha
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Coronary Artery Disease|Myocardial Infarction|Acute Coronary Syndrome|Angina, Stable|Coronary Restenosis|Myocardial Ischemia|Angina, Unstable|Coronary Stenosis|Angina Pectoris|Inflammation|ST Elevation Myocardial Infarction|Thrombosis|Coronary Disease
Phase 3: Coronary Artery Disease|Arteriosclerosis|Myocardial Ischemia|Coronary Stenosis|Coronary Occlusion
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ONYSOVER | N/A |
Recruiting |
Myocardial Ischemia|Coronary Artery Disease |
2025-12-31 |
|
ZEVS-HBR | N/A |
Recruiting |
Coronary Artery Disease |
2024-02-28 |
|
DEBORA | N/A |
Terminated |
Coronary Artery Disease|Myocardial Ischemia |
2021-09-29 |
|
CNUH-2017-319 | N/A |
Completed |
Myocardial Ischemia|Coronary Artery Disease |
2021-03-18 |